source
- Sanofi pays Regeneron $1 billion upfront to co-develop four early-stage immunology assetsSanofi has agreed to pay Regeneron an upfront fee of $1 billion to partner on four early‑stage immunology programs, a move intended to capture the success of their joint Dupixent antibody. Dupixen…
- BMS flags liver injury cases, including a death, in Phase 3 trial of pulmonary fibrosis drug admilparantBristol Myers Squibb has amended the protocol for its Phase 3 pulmonary fibrosis study of admilparant after reporting several liver injury events, one of which resulted in a patient death. The comp…